CGT 研究的前景和技術發展的機會

CGT Research Outlook and Technology Growth Opportunities

出版日期: 2024年08月05日 | 出版商:

Frost & Sullivan | 英文 76 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

資本利得稅狀況評估

過去 10 年來，CGT 周圍的環境發生了巨大變化。超過 80 種 CGT 產品在全球範圍內上市，其中 34 種細胞和基因療法僅在 2023 年就獲得 FDA核准。不斷增加的產品平臺和臨床成功率正在推動對新技術平台開發、製造能力和擴展到新疾病領域的需求。

過去五年，專利格局、投資格局和臨床試驗空間持續成長和活躍。所有這三個領域都對資本利得稅的成長做出了重大貢獻，並顯示出資本利得稅未來的巨大潛力。 CGT領域主要分為三大類：細胞療法、基因療法和基因改造細胞療法，這三者在過去幾年中都取得了良好的進展。 CAR-T和CAR-NK等基因改造細胞療法有許多臨床計畫正在進行中，預計在未來幾年將具有較高的臨床療效。

除了血液學和腫瘤學之外，CGT 開發人員還在開拓糖尿病、心血管疾病和神經系統疾病等新疾病領域，這可能會推動對 CGT 的需求。

本報告涵蓋了CGT的發展現狀和趨勢。展示出廣泛採用新技術來提高 CGT 的協作環境將改變 CGT 開發和製造的端到端能力。

由於載體設計、細胞株製造、CGT 製造能力數位化以及端到端 CGT 開發中的人工智慧整合等技術的持續發展，專利活動處於高水準。創業投資新興企業看到了未來幾年資本利得稅領域的巨大潛力，並正在支持新創公司和中型資本利得稅開發商加速其管道建設。未來幾年，獲得監管部門核准的 CGT 數量預計將增加兩倍，並將實施政策以增加患者的可及性。

最近促進創新的努力和研究加速器
CGT 研究和開發的全球趨勢
CGT發展的新技術領域
載體的選擇取決於適應症和基因改造基因表現
病毒載體工程提升安全性和功能性
向量工程創新
從自體細胞療法轉變為同種異體細胞療法的轉變仍在繼續
CGT 製造的新技術趨勢
轉向 CGT 製造的未來工廠
CGT 平台與生物製藥公司最近為加速 CGT 開發而進行的引人注目的合作

CGT臨床試驗現狀

基因治療臨床管線開發
基因改造細胞療法的臨床進展
幹細胞治療的臨床管道開發

CGT 中的成長機會領域

成長機會1：擴大CDMO產能與能力
成長機會 2：技術授權合作夥伴關係
成長機會 2：技術授權合作夥伴關係
成長機會3：轉向針對慢性病的CGT開發

附錄

技術成熟度等級 (TRL)：解釋

下一步

成長機會的好處和影響
下一步
下一步
免責聲明

簡介目錄

Product Code: DAE6

CGT Landscape Assessment

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, and expansion to new disease areas.

Over the past five years, the patent landscape, investment landscape, and clinical trial segment have had consistent growth and activity. All three segments contribute extensively to the growth of CGTs and showcase the promising potential of CGTs for the future. The CGT landscape has three main categories of therapies: cell therapies, gene therapies, and gene-modified cell therapies, with all three progressing well over the past years. Gene-modified cell therapies, such as CAR-T and CAR-NK, have a higher number of clinical programs in the pipeline and are expected to have a high clinical impact in the coming years.

CGT developers are exploring new disease areas, apart from hematological conditions and oncology, to include diabetes, cardiovascular diseases, and neurological conditions, which will boost the demand for CGTs.

The report covers the developments and trends in the CGT landscape. A collaborative environment showing the high adoption of new technologies to improve CGTs will transform the end-to-end capabilities in CGT development and manufacturing.

Patent activity is high because of consistent developments in technology for vector design, cell line manufacturing, digitalization of CGT manufacturing capabilities, and AI integration across the end-to-end CGT development. Venture capital firms see huge potential in the CGT segment in the coming years and have been constant supporters in backing start-ups and mid-sized CGT developers to accelerate their pipelines. In the coming years, the number of CGTs receiving regulatory approvals is predicted to multiply by three fold, and policies will be put in place to increase patient accessibility.

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints
Macro to Micro Visioning and Implications
Snapshot of CGT Development
Global Growth of CGT Approvals
CGT R&D Outlook
Manufacturing Expansion: Catalysts for CGT Manufacturing

CGT Patent Analysis

CGT-Overall Patent Trends
IP Landscape Gene-modified Cell Therapies
Top Patent Applicants in Gene-modified Cell Therapies
IP Landscape-Gene Therapies
Top Patent Applicants in Gene Therapies
IP Landscape Stem Cell Therapies
Top Patent Applicants in Stem Cell Therapies
An Overview of the Patent Landscape in CGTs

CGT Investment Landscape

Investment Trends in the CGT Landscape
Investment Trends in the CGT Expansion of Manufacturing Units
Investments in CGT Technology Platforms
Growing Mergers and Acquisitions
Early-stage CGT Investment Trends by Venture Capitalists
GV, United States
SAMSARA BIOCAPITAL, United States
ARCH VENTURE PARTNERS, United States
OrbiMed, United States
ALEXANDRIA, United States
RA CAPITAL, United States

CGT Publication Trend

Publication Trends in CGT

R&D Outlook across the Value Chain

Recent Initiatives and Research Accelerators Driving Innovations
Global Trends in CGT R&D
Emerging Technology Areas in CGT Development
Choice of Vector Depends on Indication and Transgene Expression
Engineering Viral Vectors to Improve Safety and Functionality
Innovations in Vector Engineering
Growing Shift from Autologous to Allogeneic Cell Therapies
Emerging Technology Trends for CGT Manufacturing
Shift toward Factory of the Future for CGT Manufacturing
Notable Recent Collaborations between CGT Platforms and Biopharma Companies to Accelerate CGT Development